Canagliflozin, a sodium glucose cotransporter 2 inhibitor, reduced the risk of cardiovascular (CV) death or hospitalized heart failure (HF) in patients with type 2 diabetes at high risk for CV disease, results from a new study in Circulation indicated.
The researchers enrolled 1,0142 participants with type 2 diabetes who were at a high CV risk and randomly assigned them to receive either canagliflozin or placebo. Participants were followed for a mean of 188 weeks, and the primary study endpoint was adjudicated cardiovascular death or heart failure requiring hospitalization.
According to the results, an overall reduction in CV death (16.3 vs. 20.8 per 1,000 patient-years; HR=0.78; 95%CI, 0.67 to 0.91) was observed in the canagliflozin group versus placebo, as well as a reduction in hospitalized HF compared to placebo (HR=0.67; 95% CI, 0.52 to 0.87). The benefit appeared to be more pronounced in patients with a history of HF at baseline (HR=0.61; 95% CI, 0.46 to 0.80) compared to those without a history of HF at baseline. (HR=0.87; 95% CI, 0.72 to 1.06; P interaction=0.021).
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.